<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39163143</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2374-4243</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Infectious diseases (London, England)</Title><ISOAbbreviation>Infect Dis (Lond)</ISOAbbreviation></Journal><ArticleTitle>Interferon gene expression declines over time post-COVID infection and in long COVID patients.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>14</EndPage><MedlinePgn>1-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/23744235.2024.2389481</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Interferons (IFNs) represent a first-line defense against viruses and other pathogens. It has been shown that an impaired and uncontrolled release of these glycoproteins can result in tissue damage and explain severe progression of coronavirus disease 2019 (COVID-19). However, their potential role in Long-COVID syndrome (LC) remains debateable.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">The objective of the present study is to shed further light on the possible role of IFNs (and related genes) gene expression patterns in the progression of COVID-19 and LC patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We carried out a multi-cohort study by analyzing the IFN gene expression patterns (using different IFN gene signatures) in five cohorts of acute COVID-19 (<i>n</i>&#x2009;=&#x2009;541 samples) and LC patients (<i>n</i>&#x2009;=&#x2009;188), and compared them to patterns observed in three autoimmune diseases (systemic lupus erythematous [<i>n</i>&#x2009;=&#x2009;242], systemic sclerosis [<i>n</i>&#x2009;=&#x2009;91], and Sj&#xf6;gren's syndrome [<i>n</i>&#x2009;=&#x2009;282]).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The data show that, while the interferon signatures are strongly upregulated in severe COVID-19 patients and autoimmune diseases, it decays with the time from symptoms onset and in LC patients. Differential pathway analysis of IFN-related terms indicates an over activation in autoimmune diseases (IFN-I/II) and severe COVID-19 (IFN-I/II/III), while these pathways are mostly inactivated or downregulated in LC (IFN-I/III). By analyzing six proteomic LC datasets, we did not find evidence of a role of IFNs in this condition.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Our findings suggest a potential role of cytokine exhaustion mediated by IFN gene expression inactivation as a possible driver of LC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>G&#xf3;mez-Carballa</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigaci&#xf3;n Sanitaria de Santiago, Universidade de Santiago de Compostela, Santiago de Compostela, Galicia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidade de Xen&#xe9;tica, Instituto de Ciencias Forenses, Facultade de Medicina, Universidade de Santiago de Compostela, and GenPoB Research Group, Instituto de Investigaci&#xf3;n Sanitaria (IDIS), Hospital Cl&#xed;nico Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Galicia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pischedda</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigaci&#xf3;n Sanitaria de Santiago, Universidade de Santiago de Compostela, Santiago de Compostela, Galicia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidade de Xen&#xe9;tica, Instituto de Ciencias Forenses, Facultade de Medicina, Universidade de Santiago de Compostela, and GenPoB Research Group, Instituto de Investigaci&#xf3;n Sanitaria (IDIS), Hospital Cl&#xed;nico Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Galicia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pardo-Seco</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigaci&#xf3;n Sanitaria de Santiago, Universidade de Santiago de Compostela, Santiago de Compostela, Galicia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidade de Xen&#xe9;tica, Instituto de Ciencias Forenses, Facultade de Medicina, Universidade de Santiago de Compostela, and GenPoB Research Group, Instituto de Investigaci&#xf3;n Sanitaria (IDIS), Hospital Cl&#xed;nico Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Galicia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Rial</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigaci&#xf3;n Sanitaria de Santiago, Universidade de Santiago de Compostela, Santiago de Compostela, Galicia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>TranslationalPediatrics and Infectious Diseases, Department of Pediatrics, Hospital Cl&#xed;nico Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Galicia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servicio de Inmunolog&#xed;a, Hospital Cl&#xed;nico Universitario Santiago de Compostela, Santiago de Compostela, Galicia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin&#xf3;n-Torres</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigaci&#xf3;n Sanitaria de Santiago, Universidade de Santiago de Compostela, Santiago de Compostela, Galicia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>TranslationalPediatrics and Infectious Diseases, Department of Pediatrics, Hospital Cl&#xed;nico Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Galicia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salas</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigaci&#xf3;n Sanitaria de Santiago, Universidade de Santiago de Compostela, Santiago de Compostela, Galicia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidade de Xen&#xe9;tica, Instituto de Ciencias Forenses, Facultade de Medicina, Universidade de Santiago de Compostela, and GenPoB Research Group, Instituto de Investigaci&#xf3;n Sanitaria (IDIS), Hospital Cl&#xed;nico Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Galicia, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Infect Dis (Lond)</MedlineTA><NlmUniqueID>101650235</NlmUniqueID><ISSNLinking>2374-4243</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID&#xa0;</Keyword><Keyword MajorTopicYN="N">RNAseq&#xa0;</Keyword><Keyword MajorTopicYN="N">interferon&#xa0;</Keyword><Keyword MajorTopicYN="N">post-COVID syndrome&#xa0;</Keyword><Keyword MajorTopicYN="N">transcriptomics&#xa0;</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>20</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>20</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39163143</ArticleId><ArticleId IdType="doi">10.1080/23744235.2024.2389481</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>